Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genomic instability is associated with response to [¹⁷⁷Lu]Lu-PSMA-I&T radioligand therapy: an exploratory, preliminary liquid biopsy analysis

22 Apr 2025

Abstract excerpt

BACKGROUND: PSMA-targeted radioligand therapies (PSMA RLT) are an effective and safe option for metastatic castration-resistant prostate cancer, but responsive subtypes and their biomarkers are not fully defined. METHODS: Plasma samples for cell-free DNA (cfDNA) analysis were collected from 17 patients undergoing [¹⁷⁷Lu]Lu-PSMA-I&T. CfDNA underwent whole-genome sequencing to establish copy number variation (CNV)...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Prostate Cancer Diagnosis and Treatment
Share to Prostate Cancer Treatment and Research
Share to Radiopharmaceutical Chemistry and Applications

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 40261406
DOI: 10.1007/s00259-025-07280-5

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genomic instability is associated with response to [¹⁷⁷Lu]Lu-PSMA-I&T radioligand therapy: an exploratory, preliminary liquid biopsy analysisPMID 40261406Read ↗

Genomic Alterations in Cell-Free DNA and Enzalutamide Resistance in Castration-Resistant Prostate CancerSemantic proximity Read ↗

Genomic characterization of metastatic castration‐resistant prostate cancer patients undergoing PSMA radioligand therapy: A single‐center experienceSemantic proximity Read ↗

Circulating tumor DNA profile recognizes transformation to castration-resistant neuroendocrine prostate cancerSemantic proximity Read ↗

Tumor fraction in cell-free DNA as a biomarker in prostate cancerSemantic proximity Read ↗

Monitoring dynamic cytotoxic chemotherapy response in castration-resistant prostate cancer using plasma cell-free DNA (cfDNA)Semantic proximity Read ↗

AR alterations inform circulating tumor DNA detection in metastatic castration resistant prostate cancer patients.Semantic proximity Read ↗

Clinical and genomic insights into circulating tumor DNA-based alterations across the spectrum of metastatic hormone-sensitive and castrate-resistant prostate cancer.Semantic proximity Read ↗

Precision Targeting in Metastatic Prostate Cancer: Molecular Insights to Therapeutic FrontiersSemantic proximity Read ↗

Future directions for precision oncology in prostate cancerSemantic proximity Read ↗

Integrative genomic and epigenomic profiling in plasma and urinary cell-free DNA improves early risk stratification of newly diagnosed prostate cancerSemantic proximity Read ↗

Cell-Free DNA Detection of Tumor Mutations in Heterogeneous, Localized Prostate Cancer Via Targeted, Multiregion Sequencing.Semantic proximity Read ↗

Circulating tumor DNA alterations in patients with metastatic castration‐resistant prostate cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.